Evaluation Of Lactobacillus As Adjuvant Among Pediatric Intensive Care Admissions In An Attempt To Prevent Acquiring Nosocomial Infections

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202405774358342

Enrollment

196

Registered

2024-05-08

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nosocomial infection in critically ill patients admitted in the pediatric intensive care unit Paediatrics

Interventions

Lacteol forte and linex

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All admitted patients to the PICU

Exclusion criteria

Exclusion criteria: - All surgical cases. - Patients with suspicion of gastrointestinal perforation or obstruction. - Patients with neutropenia (less than or equal 0.5×109 cells/ liter). - Patients with history of chronic immunological diseases or receiving immunosuppressive drugs for the previous 3 months before admission. - Oncological patients on treatment. - Patients on breast feeding during the PICU stay. - Patients receiving probiotics in the 2 weeks before admission - Patients with absolute contraindication to eternal medication - Patients with Acute pancreatitis. - Patients deceased within the first 72 hours from admission

Design outcomes

Primary

Measure	Time frame
Hospital Acquired Infections ;28-days mortality	—

Secondary

Measure	Time frame
Length of PICU stay. ;Length of hospitalization	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026